Knight Therapeutics Reports Third Quarter 2026 Results
Achieved nine-month record-high revenues of over $430 million and Adjusted EBITDA 1 of over $76 million Raised 2026 gu idance to revenues of $560 million to $570 million and Adjusted EBITDA 1 of approximately 17.5% of revenues Raised peak annual revenues for pipeline and launched pipeline products to over $300 million